Custom RGD peptide-conjugated lipid nanoparticle (RGD-LNP) development for integrin-targeted RNA delivery, peptide-lipid synthesis, surface conjugation, formulation screening, and functional targeting evaluation.
RGD (Arg-Gly-Asp) peptides recognize several integrins, including αvβ3 and αvβ5, which can be expressed on activated endothelial cells and selected tumor cell populations. Displaying an appropriate RGD ligand on an LNP may improve receptor-dependent interaction, but the result depends on the peptide sequence, integrin expression, ligand accessibility, and the underlying lipid formulation.
BOC Sciences supports peptide-functionalized lipid nanoparticle development, including linear RGD, cyclic RGD, multivalent RGD, and iRGD designs. Our work integrates peptide chemistry, lipid anchoring, particle preparation, and biological readouts so researchers can distinguish simple nanoparticle uptake from effective intracellular payload delivery.
We tailor RGD-LNP systems to siRNA, mRNA, other nucleic acids, selected biomolecules, small molecules, and imaging probes. Each project is planned around a defined target-cell model, appropriate non-targeted controls, and measurable formulation and functional endpoints.
RGD-Functionalized Lipid Nanoparticle Illustration
Our integrated services cover RGD ligand development, LNP surface engineering, payload loading, integrin-targeting studies, and formulation reproducibility. The screening plan is customized to the peptide format, cargo, and intended cellular readout.
We choose peptide architecture and coupling positions to preserve the integrin-binding motif and support stable association with the nanoparticle surface.
We develop modification conditions that expose the RGD motif without unnecessarily disturbing particle assembly or payload retention.
We coordinate the RGD surface layer with the ionizable lipid core so targeting modifications do not compromise cargo protection and intracellular function.
We use complementary analytical methods to connect peptide incorporation with particle structure, stability, and reproducibility.
Our evaluation plans test whether RGD modification adds genuine receptor-dependent delivery rather than fluorescence uptake alone.
We help establish repeatable preparation and surface-modification conditions for comparative formulation research.
BOC Sciences helps clients choose a starting format and then confirm the choice with receptor-level data. Peptide handling options also extend to our LNP-based peptide delivery work when the peptide itself is the payload.
Linear sequences such as RGD, RGDS, and GRGDSPK are the simplest option and are often used for fast screening and mechanistic work.
Cyclic formats such as c(RGDfK) and c(RGDyK) constrain the peptide into a receptor-preferred conformation and are the most common choice for integrin-targeted nanoparticle work.
Multivalent display places several RGD units on one scaffold or one lipid anchor, which raises apparent binding strength through avidity rather than through single-site affinity.
iRGD adds a tissue-penetration step to integrin binding. After an initial proteolytic cleavage, a CendR motif is exposed and engages a second receptor that supports deeper transport into tissue.
Tell us your integrin expression profile, payload, and readout. We will propose a starting ligand format and a comparison plan with matched controls.
How the peptide reaches the particle surface often matters more than which peptide you chose. The route determines whether the peptide sees organic solvent and low pH, how much of it ends up on the outside, how uniformly it is distributed, and how reproducible the result is between batches. BOC Sciences runs the routes below as comparable options rather than as fixed packages.
A pre-made RGD-PEG-lipid is transferred into already-formed LNPs. This is the mildest route for a payload that is sensitive to re-formulation.
The LNP is first assembled with a reactive lipid such as DSPE-PEG-maleimide, and the RGD peptide is coupled afterwards. The peptide never passes through the organic phase or the low-pH loading step.
The RGD-lipid is part of the lipid mixture from the start and is displayed during self-assembly. This gives the most direct control over the final composition.
Chemistry decides where the bond forms on the peptide. We work across thiol-maleimide and thiol-vinyl sulfone coupling for cysteine-bearing peptides, copper-free DBCO-azide click chemistry when no thiol is available, EDC or NHS amine-carboxyl coupling for sequences without a designed handle, and disulfide or cleavable linkers for ligands meant to detach later.
The spacer between anchor and peptide sets how far the ligand stands off the surface. Options run from short PEG350 to PEG1000 arms through the standard PEG2000 length to PEG3400 or PEG5000, with alkyl anchors from sheddable C14 or DMG types to long C18 or DSPE types.
Instead of attaching the peptide to the end of a long PEG arm, the peptide can be linked directly to a lipid tail and displayed at high density. This is a useful alternative when a PEG spacer gives no measurable gain.
Integrin-Oriented Target Recognition
Selected RGD ligands interact with integrins expressed by certain endothelial and tumor cell models. Targeting can be investigated with integrin-high versus integrin-low comparisons and receptor-blocking controls rather than inferred from fluorescence uptake alone.
Small, Chemically Adaptable Ligand Format
RGD peptides can be synthesized with terminal or side-chain handles, cyclic constraints, or branched architectures. These options help tailor coupling chemistry and ligand presentation while retaining an analytically tractable conjugate.
Modular Integration with Multiple Payloads
RGD surface designs can be tested alongside RNA, molecular probes, and selected non-nucleic-acid cargos. Separating surface engineering from core formulation can simplify controlled comparisons across peptide variants.
Quantifiable Design and Mechanism Variables
Peptide feed, attachment conversion, receptor accessibility, particle properties, uptake, and payload function can be measured as distinct endpoints. This supports data-driven optimization and more defensible interpretation of targeting claims.
BOC Sciences develops RGD-modified LNPs for many payload types used in integrin-related delivery research.
| Payload Type | Supported Uses & RGD-LNP Development Considerations | Request Information |
|---|---|---|
| RGD-LNP Development for siRNA and miRNA | Suitable for gene silencing studies in integrin-expressing tumor cells, activated endothelial cells, and stromal cell models. Development focuses on duplex encapsulation, free RNA reduction, RGD density, receptor-dependent uptake, and knockdown comparison against matched untargeted LNPs. See also our work on lipid nanoparticles for siRNA delivery. | Inquiry |
| RGD-LNP Development for mRNA and Reporter RNA | Used for reporter expression, protein expression, and formulation comparison studies. Development considers mRNA integrity, encapsulation efficiency, RGD surface exposure, particle stability, and expression readouts in integrin-positive versus integrin-low cell models. Related options are covered under lipid nanoparticles for mRNA delivery. | Inquiry |
| RGD-LNP Development for saRNA and circRNA | Applicable to RNA systems that need stronger payload protection and sustained expression. We evaluate RGD-lipid compatibility, encapsulation behavior, particle attributes, and expression durability under matched control conditions. | Inquiry |
| RGD-LNP Development for pDNA and CRISPR Systems | Supports plasmid expression work and nuclease-based editing studies using gRNA/mRNA pairs or ribonucleoprotein formats. Development covers co-loading ratio control, particle uniformity, RGD-lipid compatibility, and editing readouts. See lipid nanoparticles for CRISPR RNP delivery for related formats. | Inquiry |
| RGD-LNP Development for Protein and Peptide | Suitable for enzymes, binding proteins, antigens, and functional peptide payloads used in integrin-related delivery research. Formulation work focuses on mild loading conditions, aggregation control, activity retention, and receptor-dependent uptake evaluation, supported by our LNP-based protein delivery experience. | Inquiry |
| RGD-LNP Development for Small Molecule | Designed for hydrophobic, amphiphilic, or ionizable small molecules used in vascular, stromal, or tumor-cell delivery research. We consider drug-lipid compatibility, loading method, leakage control, particle stability, RGD modification, and release behavior. Options are also described under lipid nanoparticles for small molecule delivery. | Inquiry |
| RGD-LNP Development for Fluorescent and Imaging | Supports fluorescent dyes, labeled RNA, labeled peptides, and contrast payloads used to study RGD-LNP binding, intracellular localization, and distribution trends. We also prepare matched fluorescent-labeled lipid nanoparticles controls without the peptide. | Inquiry |
| RGD-LNP Development for Custom and Co-Loaded Payloads | Developed for unusual payloads, dual-payload systems, or early feasibility studies. We evaluate payload compatibility, loading sequence, RGD modification route, particle stability, and target-cell delivery performance. | Inquiry |
✔ RGD Signal Masked by the PEG Corona
A long, flexible PEG spacer can fold back over the peptide and reduce the number of productive receptor contacts. We screen spacer length, total PEG-lipid content, and anchor type, then track exposure with zeta potential shift and peptide-specific binding assays rather than with formulation input alone.
✔ Particle Growth or Broad PDI After Peptide Modification
Adding a peptide-lipid changes the packing of the lipid assembly and can push size and PDI outside the intended range. We rebalance ionizable lipid, helper lipid, cholesterol, and PEG-lipid content, and adjust mixing conditions until the particle profile is restored.
✔ Low Coupling Efficiency and Unstable Ligand Anchoring
A peptide can be present in the reaction and still end up off the particle, or attached through the wrong residue. We quantify conjugated versus free peptide, check reaction pH and time, and compare short and long alkyl anchors when the ligand needs to stay on the surface for the whole study window.
✔ Higher Uptake Without Higher Payload Function
More particle inside the cell does not guarantee more mRNA expression, more silencing, or more editing. We separate binding, uptake, intracellular localization, and endosomal release, and use our LNP transfection troubleshooting services and LNP endosomal escape evaluation to locate the limiting step.
✔ Unclear Integrin Contribution to Cellular Uptake
Nanoparticles enter cells through several routes at once, so an uptake gain is not automatically receptor-driven. We design matched untargeted controls, free RGD competition groups, receptor-blocking conditions, and integrin-high versus integrin-low cell pairs so the mechanism can be stated with evidence.
✔ Off-Target Accumulation in Liver and Spleen
Even a well-targeted LNP is still cleared largely through hepatobiliary and mononuclear phagocyte routes. We adjust surface charge, ligand density, and PEG-lipid level, then read the actual tissue pattern through nanoparticle in vivo distribution analysis instead of assuming the change worked.
BOC Sciences helps research teams troubleshoot ligand exposure, conjugation efficiency, particle instability, integrin-dependent uptake, off-target distribution, and functional delivery readouts.
We establish the cargo, intended target cells, integrin profile, desired uptake or functional endpoint, and study environment. Together with the client, we define appropriate RGD and non-targeted comparators and agree on formulation attributes to monitor.
We select a linear, cyclic, multivalent, or iRGD format, its attachment position, and a PEG-spaced or direct lipid anchor. The design plan compares post-insertion, PCT, or ILT when their processing differences may influence functional delivery.
We prepare candidate formulations using a suitable process, including microfluidic LNP production where appropriate. Candidate comparisons track RGD feed, attachment or insertion, lipid composition, particle size, PDI, and payload loading under matched conditions.
We integrate physicochemical data with integrin-dependent binding, cell uptake, and functional cargo readouts. Selected candidates are compared across repeat preparations, and the resulting dataset supports a transparent decision about further formulation optimization.
Share your model, integrin expression data, and readout. We will propose an RGD-LNP design with comparison arms, controls, and decision criteria before any formulation work starts.
Challenge: A team in the Netherlands was developing an LNP for a 21-nucleotide siRNA in αvβ3-high tumor models. Their in-line linear RGD-PEG2000-DSPE at 1 mol% measured 88 nm, PDI 0.14, EE above 80%, but uptake was only 1.3 times control, tumor signal stayed below 1% ID/g, and competition with free peptide changed almost nothing.
Diagnosis: Review showed the problem was presentation, not biology: the PEG2000 spacer shielded a short linear peptide that bound weakly and degraded in incubation, and the in-line route exposed it to ethanol and low pH. A near-flat zeta potential confirmed shielding.
Solution: Two arms were built. Arm one post-conjugated c(RGDfK)-Cys onto 1 mol% DSPE-PEG2000-maleimide at pH 6.8 for two hours, titrated at 0.17 to 1.0 mol%. Arm two removed the spacer, co-formulating C18-c(RGDfK) at 1.5 and 5 mol% with C18-PEG350. Twelve candidates were screened on size, PDI, zeta, EE, uptake, 50 μM competition, and knockdown, with EE re-checked through our LNP encapsulation efficiency optimization workflow.
Result: The 0.5 mol% post-conjugated candidate was best: 92 nm, PDI 0.12, EE above 85%, uptake 4.2 times control falling to 1.4 times under competition, silencing from 38% to 71%, and 5% RSD across three repeats. The 1.0 mol% and 5 mol% arms were set aside for PDI and size drift.
Challenge: A university group in Canada wanted localized mRNA delivery to integrin-rich tissue in a rodent model. Expression appeared mainly in liver and spleen, and raising C18-RGD from 0 to 5 mol% shifted zeta only from −1.6 to −4.8 mV, so the team could not tell if the peptide was hidden or absent.
Diagnosis: The near-flat zeta potential was the key signal: an exposed peptide shifts potential as input rises, so a flat profile across a five-fold increase meant PEG2000 was shrouding C18-RGD.
Solution: Only the surface changed: C18-PEG2000 became C18-PEG350, with C18-RGD at 0, 1.5, and 5 mol%, plus a C14-PEG350 arm and a DSPE-PEG2000-c(RGDfK) control. Nine candidates were checked for size, PDI, zeta, EE, in vitro uptake, and tissue distribution.
Result: The 5 mol% C18-RGD with C18-PEG350 candidate was best: 135 nm, PDI 0.16, zeta −16 mV, confirming exposure, with 3.1 times expression at the target site and 40 to 60% less liver and spleen signal. The C14 arm exceeded 200 nm; the PEG2000 arm showed no gain, so the client kept a high-density design near 80% EE.
Rapid Response and Dedicated Project Support
A single technical contact owns your project, answers formulation questions directly, and flags drift early so small decisions do not stall the campaign.
Global Teams Across Multiple Regions
Teams in North America, Europe, and Asia-Pacific hand off across time zones, and data packages are formatted to fit your internal documentation habits.
End-to-End RGD-LNP Development Services
Peptide selection, conjugation route, density and spacer screening, formulation, characterization, and integrin evaluation run as one workflow, so ligand and particle teams stay aligned.
Strong Peptide and Lipid Synthesis Capabilities
Linear, cyclic, multivalent, and iRGD sequences plus DSPE, DMG, DPPE, cholesterol, and alkyl anchors are made in-house with defined handles, shortening the loop between a design change and a testable material.
Extensive Inventory of Ready-to-Use Starting Materials
Ionizable lipids, helper phospholipids, cholesterol, PEG-lipids at several chain lengths, and functionalized lipids for coupling are stocked, so screening can start in days and comparison arms add without a restart.
Linear RGD peptides provide a flexible Arg-Gly-Asp motif and are useful for early ligand screening, but their receptor preference and stability can differ considerably by sequence. Cyclic RGD peptides restrict motif geometry and may offer stronger binding or improved selectivity toward particular integrins, such as αvβ3, depending on the ring structure. iRGD adds a distinct tissue-penetration mechanism: after integrin binding and appropriate proteolytic processing, an exposed CendR motif can interact with neuropilin-1 (NRP-1). That sequence of events is model dependent. For LNP design, peptide attachment position, linker length, surface density, and target-cell receptor expression should be assessed together rather than selecting a peptide based on its name alone.
There is no universally best attachment route. Post-insertion introduces pre-made RGD-PEG-lipids into previously assembled LNPs and is convenient for comparative screening, although the fraction actually inserted must be measured. Post-conjugation targeted (PCT) modification attaches functionalized RGD to reactive groups displayed on preformed LNPs, allowing coupling to be optimized after payload encapsulation. In-line targeted (ILT) formulation incorporates an RGD-lipid conjugate directly during particle assembly and reduces post-formulation handling, but bulky ligands may affect particle formation. Thiol-maleimide and copper-free click reactions can support surface coupling when their respective handles are available. Final selection should compare ligand accessibility, residual free peptide, size distribution, payload integrity, and functional delivery, not formulation convenience alone.
First verify that the chosen cell model expresses the integrin subtypes expected to interact with the selected RGD ligand. Then compare RGD-LNPs with composition-matched non-targeted LNPs and, where practical, use an inactive or scrambled peptide control. Competition with free ligand, receptor-blocking reagents, and integrin-high versus integrin-low cell models help distinguish specific binding from nonspecific nanoparticle adsorption. Flow cytometry and microscopy quantify cell association and intracellular localization, but neither technique by itself establishes productive delivery. For siRNA or mRNA, include knockdown or reporter expression measurements alongside cargo integrity assessments. If tissue distribution is measured, interpret particle-label localization separately from functional payload activity.
Yes. BOC Sciences supports RGD-LNP development for siRNA, mRNA, selected oligonucleotides, and other research cargo, depending on payload compatibility and intended experimental endpoints. Our services include linear or cyclic RGD ligand selection, peptide-lipid conjugate synthesis, PEG spacer engineering, surface modification, lipid composition optimization, encapsulation evaluation, and particle characterization. For siRNA projects, functional assessment may focus on target-gene knockdown; for mRNA projects, reporter or protein expression can provide a more relevant endpoint. Integrin-related uptake can also be evaluated using matched controls. Rather than applying one standard RGD formulation to every payload, we establish a project-specific screening strategy based on cargo properties, target-cell biology, and the required functional readouts.
To scope a custom RGD-LNP project, customers can share the intended payload type, available sequence or molecular characteristics, target cell or tissue model, known integrin expression, and the main experimental objective. Existing LNP compositions, encapsulation results, particle-size data, or previous cellular uptake measurements are helpful but not essential. It is also useful to indicate whether the priority is ligand synthesis, surface conjugation, formulation optimization, cellular evaluation, or an integrated development package. BOC Sciences can use this information to recommend suitable peptide formats, preparation routes, control formulations, and analytical methods. Where feasibility remains uncertain, an initial small-scale comparison can establish a practical direction before more extensive formulation development.
